SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

HOPE-3s 24-month open-label extension data presented at the World Muscle Society, including a reported 76% slowing of upper-limb decline after placebo patients switched to deramiocel, is driving attention. Many traders view the results as support for FDA approval ahead of the Nov. 22 decision, while others question whether the FDA will accept the analyses given the ongoing statistical-analysis-plan dispute.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances raised revenue outlook, driven by stronger demand for Amtagvi, has fueled a sharp rally and analyst target increases. Traders are broadly bullish and debate whether heavy short interest could amplify the move, while some flag overbought conditions and profit-taking; upcoming lung-cancer data is seen as another potential catalyst.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

TTDs steep selloff to multiyear lows is being tied to slowing growth, weak advertising-spend expectations and concerns that Amazon and other large platforms are intensifying competition. Traders are divided between viewing the cash-generative business as oversold and arguing that weak outlook, execution and management issues leave further downside risk; Apple/Safari ad-blocking claims remain contested speculation.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

A federal judge paused the cannabis rescheduling case while considering whether to add a government watchdog report on agency procedures to the record, delaying a potential Schedule III decision. Traders are split between viewing the pause as a serious setback that extends uncertainty and treating it as a temporary procedural delay and buying opportunity; the earlier medical-marijuana rule remains in place.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is under pressure amid concerns that Kalshi and Polymarket are taking wagering share, while added spending to compete in prediction markets could weigh on margins. Traders debate whether DKeXs rapid volume growth and sportsbook momentum can offset the competitive and regulatory risks.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

COMPs sharp rebound and apparent breakout have traders focused on its capped 10 million token supply and potential DeFi upside, with some also speculating that crypto legislation or broader altcoin strength could provide a tailwind. Others remain skeptical, calling the move speculative and looking for a sustained break above resistance before treating it as a trend change.

Fair Isaac Corp. engages in the provision of decision management solutions. It operates through the Software and Scores segments. The Software segment includes pre-configured analytic and decision management solutions designed for a specific type of business need or process. The Scores segment focuses on business-to-business scoring solutions and services, business-to-consumer scoring solutions and services including myFICO solutions for consumers and associated professional services. The company was founded by Bill Fair and Earl Isaac in 1956 and is headquartered in San Jose, CA.

Fair Isaac Corp.

Fair, Isaac Corp.

The FHFAs move to let VantageScore compete alongside FICO in Fannie Mae and Freddie Mac mortgage pricingalong with lenders interest in the lower-cost alternativehas raised concerns that FICOs mortgage-scoring moat and pricing power could weaken, driving a sharp selloff. Traders are divided between seeing a lasting competitive threat and viewing the decline as an overreaction, with some expecting a rebound while others warn of further repricing.

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

A sharp, high-volume rally in QNT has fueled talk of a breakout and a possible low-supply squeeze, with traders linking the move to reported Oracle and bank-infrastructure developments and Quants presence at Sibos. Bullish calls for further gains contrast with profit-taking and skepticism about whether those partnerships will create meaningful demand for the token, amid volatile pullbacks.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vandas Phase III Hetlioz study in delayed sleep-wake phase disorder met its primary endpoint, drawing attention to a potential label expansion for an already-approved drug; the company plans to discuss the results with the FDA before filing a supplemental application. Traders largely welcomed the readout and anticipated a commercial opportunity, while some noted the small study size and questioned how durable the stock reaction would be.

Carnival Corp. Ltd. engages in the operation of cruise ships. It operates through the following business segments: North America Cruise Operations, Europe Cruise Operations, Cruise Support, and Tour and Others. The North America Cruise Operations segment includes the Carnival Cruise Line, Holland America Line, Princess Cruises, and Seabourn. The Europe Cruise Operations segment consists of AIDA, Costa, Cunard, and P&O Cruises (UK). The Cruise Support segment represents port destinations and private islands for the benefit of its cruise brands. The Tour and Other segment operates hotel and transportation operations of Holland America Princess Alaska Tours. The company was founded in 1972 and is headquartered in Miami, FL.

Carnival Corporation Ltd.

Carnival Corp

Carnivals quarterly results beat expectations, prompting a sharp rally, while raised full-year guidance and record bookings for 2027 strengthened the bullish case. Traders remain divided over higher fuel costs and softer near-term guidance, with some questioning whether the gains can hold.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


Schadole_n_Beans

Giovanni Scarmozza